In vitro activity of fosfomycin against ESBL-producing enterobacteria of urinary origin;Actividad in vitro de fosfomicina frente a enterobacterias de origen urinario productoras de betalactamasas de espectro extendido

Revista Espanola de Quimioterapia

Volumn 22, Issue 1, 2009, Pages 25-29

  Hernandez Ma S ^a   Garcia Rodriguez J A ^a,b   Munoz J L ^a,b  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Escherichia coli; Extended spectrum beta lactamase (ESBL); Fosfomycin; Klebsiella pneumoniae

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CIPROFLOXACIN; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN; GENTAMICIN; NITROFURANTOIN;

AGAR DILUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; ENTEROBACTERIACEAE; EPSILOMETER TEST; ESCHERICHIA COLI; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; NONHUMAN; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; ESCHERICHIA COLI; FOSFOMYCIN; HUMANS; KLEBSIELLA PNEUMONIAE; URINE;

EID: 68549083465     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Hooton TM. Practice guidelines for urinary tract infections in the era of managed care. Int J Antimicrob Agents 1999;11:241-245 (Pubitemid 29231968)
2. Rodríguez Baño J, Navarro MD, Romero L, Martínez L, Muniain MA, Perea EJ, et al. Epidemiology and clinical features of infections caused by extended-spectrum B-lactamase-producing Escherichia coli in non-hospitalized patients. J Clin Microbiol 2004;42:1089-1094 (Pubitemid 38332830)
3. Valverde Romero ED, Parras Padilla T, Herrero Hernández A, Pérez Grande R, Fernández Vázquez M, García García MI, et al. Prevalence of clinical isolates of Escherichia coli and Klebsiella spp. producing multiple extended-spectrum β-lactamases. Diagn Microbiol Infect Dis 2007;59:433-437 (Pubitemid 350184221)
4. García García MI, Muñoz Bellido JL, García Rodríguez JA. In vitro susceptibility of community-acquired urinary tract infection pathogens to commonly used antimicrobial agents in Spain. A comparative multricenter study (2002-2004). J Chemother 2007;19:263-270
5. Alós JI, Serrano MG, Gómez Garcés JL, Perianes J. Antibiotic resistance of Escherichia coli from community-acquired urinary tract infections in relation to demographic and clinical data. Clin Microbiol Infect 2005;11:199-203. (Pubitemid 40352766)
6. National Committee for Clinical Laboratory Standards (NCCLS). Performance standards for antimicrobial susceptibility testing; Fifteenth informational supplement. Wayne, PA: NCCLS, 2005.
7. Fernández Vázquez M, Muñoz Bellido JL, Garcia García MI, Garcia-Rodríguez JA. Salmonella enterica serovar Enteritidis producing a TEM-52 β-lactamase: first report in Spain. Diagn Microbiol Infect Dis 2006;55:245-246
8. Valverde Romero E, Parras Padilla T, García García MI, Delgado Ronda N, Herrero A, et al. Salmonella enterica serovar Infantis producing a CTX-M-9 β-lactamase. Antimicrob Agents Chemother 2005;49:2142-2143 (Pubitemid 40631643)
9. Hernández JR, Martínez-Martínez L, Cantón R, Coque TM, Pascual A; Spanish Group for Nosocomial Infections (GEIH). Nationwide study of Escherichia coli and Klebsiella pneumoniae producing extended-spectrum β-lactamases in Spain. Antimicrob Agents Chemother 2005;49:2122-2125
10. Cueto M, Hernández JR, López Cerero L, Morillo C, Pascual A. Actividad de fosfomicina sobre cepas de Escherichia coli y Klebsiella pneumoniae productoras de betalactamasas de espectro extendido. Enferm Infecc Microbiol Clin 2006;24:613-616
11. Kahlmeter G. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO-SENS Project. J Antimicrob Chemother 2003;51:69-76. (Pubitemid 36163829)